Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C16H22N4O3 |
| Molecular Weight | 318.3709 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=C(NC(=N2)[C@H]3CCC(=O)C3)C(=O)N(CCC)C1=O
InChI
InChIKey=RUHGOZFOVBMWOO-JTQLQIEISA-N
InChI=1S/C16H22N4O3/c1-3-7-19-14-12(15(22)20(8-4-2)16(19)23)17-13(18-14)10-5-6-11(21)9-10/h10H,3-9H2,1-2H3,(H,17,18)/t10-/m0/s1
| Molecular Formula | C16H22N4O3 |
| Molecular Weight | 318.3709 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Apaxifylline is an adenosine A1 receptor antagonist that was under investigation with Boehringer Ingelheim as a potential neuroprotective drug for the treatment of dementia. Apaxifylline was able to antagonize scopolamine-induced deficits in the rat in a memory task. A single oral application of apaxifylline 90 min before the rats received the noxious stimulus significantly attenuated the scopolamine-induced deficits observed during the retention trial of the rat in the passive avoidance paradigm. Apaxifylline treatment does not influence motility.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9203562
Curator's Comment: rat data
Single dose 1 mg/kg and 3 mg/kg
Route of Administration:
Oral
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:12:44 GMT 2025
by
admin
on
Mon Mar 31 18:12:44 GMT 2025
|
| Record UNII |
OG8HSX6N6H
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
NCI_THESAURUS |
C1509
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
151581-23-6
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
60949
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
OG8HSX6N6H
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
SUB05536MIG
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
100000086976
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
C81046
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
7264
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
GG-37
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
CHEMBL2104538
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY | |||
|
DTXSID801350965
Created by
admin on Mon Mar 31 18:12:44 GMT 2025 , Edited by admin on Mon Mar 31 18:12:44 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|